Acquisition brings an advanced, highly differentiated treatment for prostate cancer, strengthening Johnson & Johnson’s longstanding commitment to innovation in the disease. Lead asset demonstrates potential to overcome key resistance pathways in prostate cancer through targeted tumor cell eradication.

RYBREVANT FASPRO™, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related reactions1-5 Approval builds on previously reported Phase 3 MARIPOSA data showing unmatched overall survival benefit of this chemotherapy-free regimen, projected to exceed four years6

CAPLYTA®, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications1,2 In pivotal trials, CAPLYTA® did not increase mean weight gain, metabolic changes, or reported sexual side effects1,2 In a six-month open-label extension safety study, safety profile was consistent with pivotal studies and 80% of MDD patients taking CAPLYTA® achieved response, with 65% of patients reaching remission from depression3 CAPLYTA® offers a new option for the 2 in 3 people who experience residual symptoms despite their current antidepressant treatment1,2,3

Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring Landmark approval supports earlier intervention and disease interception of multiple myeloma for the first time